An evaluation of the tissue distribution and the selective tumor trafficking of TNF [tumour necrosis factor]-bound colloidal gold (CYT-6091) following intravenous administration in subjects with primary and metastatic cancer undergoing surgical resection.
Phase of Trial: Phase 0
Latest Information Update: 01 May 2012
At a glance
- Drugs CYT 6091 (Primary)
- Indications Adrenal cancer; Breast cancer; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cancer; Sarcoma
- Focus Pharmacokinetics
- 01 May 2012 Trial phase changed from I to 0 as reported by ClinicalTrials.gov.
- 15 Mar 2012 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.